Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors

Lingaku Lee, Tetsuhide Ito, Hisato Igarashi, Masami Miki, Nao Fujimori, Ken Kawabe, Robert T. Jensen, Yoshihiro Ogawa